The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma
Beck anxiety and depression inventory
SF-36 quality of life survey
TSH suppression
differentiated thyroid carcinoma
subclinical hyperthyroidism
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
23 06 2020
23 06 2020
Historique:
received:
21
02
2019
accepted:
19
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
26
10
2021
Statut:
epublish
Résumé
Overt thyroidism is known to cause neuropsychiatric disorders but studies on subclinical hyperthyroidism (SCH) are limited. Subclinical hyperthyroidism induction by administering L-Thyroxine (LT4) is the standard treatment method in differentiated thyroid carcinoma (DTC) follow-up. Our aim was to investigate whether anxiety, depression and quality of life are affected in DTC patients followed-up with exogenous SCH. The patients were divided into exogenous SCH by LT4-DTC (n = 127), euthyroid-DTC (n = 66) and exogenous euthyroid-benign thyroid noduüle (BTN) who underwent thyroidectomy for benign thyroid pathology (n = 85) groups. The rate of moderate/severe anxiety was significantly higher in SCH-DTC than euthyroid-BTN group (27.5%, n = 35 vs. 9.4%, n = 8) (P = 0.001). TSH levels and Beck anxiety inventory (BAI) scores were significantly negatively correlated(P = 0.009 r = –0.16). Free T4 and BAI were significantly positively correlated (P = 0.04 r = 0.4). The groups were similar in terms of depression severity (P = 0.15). Subclinical hyperthyroid-DTC group scored significantly lowerthan euthyroid-BTN group in all scales of SF-36 quality of life survey. LT4-induced SCH, which is a part of traditional DTC treatment, can exacerbate the anxiety symptoms in patients and disrupt their quality of life, depending on the level of fT4.
Sections du résumé
Background/aim
Overt thyroidism is known to cause neuropsychiatric disorders but studies on subclinical hyperthyroidism (SCH) are limited. Subclinical hyperthyroidism induction by administering L-Thyroxine (LT4) is the standard treatment method in differentiated thyroid carcinoma (DTC) follow-up. Our aim was to investigate whether anxiety, depression and quality of life are affected in DTC patients followed-up with exogenous SCH.
Materials and methods
The patients were divided into exogenous SCH by LT4-DTC (n = 127), euthyroid-DTC (n = 66) and exogenous euthyroid-benign thyroid noduüle (BTN) who underwent thyroidectomy for benign thyroid pathology (n = 85) groups.
Results
The rate of moderate/severe anxiety was significantly higher in SCH-DTC than euthyroid-BTN group (27.5%, n = 35 vs. 9.4%, n = 8) (P = 0.001). TSH levels and Beck anxiety inventory (BAI) scores were significantly negatively correlated(P = 0.009 r = –0.16). Free T4 and BAI were significantly positively correlated (P = 0.04 r = 0.4). The groups were similar in terms of depression severity (P = 0.15). Subclinical hyperthyroid-DTC group scored significantly lowerthan euthyroid-BTN group in all scales of SF-36 quality of life survey.
Conclusion
LT4-induced SCH, which is a part of traditional DTC treatment, can exacerbate the anxiety symptoms in patients and disrupt their quality of life, depending on the level of fT4.
Identifiants
pubmed: 32490648
doi: 10.3906/sag-1902-176
pmc: PMC7379439
doi:
Substances chimiques
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
870-876Informations de copyright
This work is licensed under a Creative Commons Attribution 4.0 International License.
Déclaration de conflit d'intérêts
All of the authors declare that they have no competing interests. The authors also certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.
Références
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
J Clin Psychiatry. 1988 Jun;49(6):229-31
pubmed: 3379028
Arch Intern Med. 2012 May 28;172(10):799-809
pubmed: 22529182
Head Neck. 2003 May;25(5):349-56
pubmed: 12692870
Arq Bras Endocrinol Metabol. 2014 Apr;58(3):274-81
pubmed: 24863090
J Consult Clin Psychol. 1988 Dec;56(6):893-7
pubmed: 3204199
Neuroendocrinology. 2016;103(3-4):291-9
pubmed: 26202797
Thyroid. 2011 Jul;21(7):695-700
pubmed: 21615309
Acta Psychiatr Scand. 2002 Jul;106(1):27-34
pubmed: 12100345
Thyroid. 2010 Feb;20(2):173-9
pubmed: 20151824
Br J Psychiatry. 1973 May;122(570):549-54
pubmed: 4717027
Prog Neuropsychopharmacol Biol Psychiatry. 1997 Aug;21(6):925-35
pubmed: 9380789
J Endocrinol. 2012 Jun;213(3):209-21
pubmed: 22454529
Eur J Endocrinol. 2011 Oct;165(4):545-54
pubmed: 21768248
Am J Clin Oncol. 2013 Aug;36(4):354-61
pubmed: 22643561
J Affect Disord. 2002 May;69(1-3):209-17
pubmed: 12103468
Endocr J. 2004 Jun;51(3):311-5
pubmed: 15256776
J Clin Endocrinol Metab. 2014 Apr;99(4):1213-9
pubmed: 24564323
Thyroid. 2012 Feb;22(2):117-24
pubmed: 22191388
Hormones (Athens). 2010 Apr-Jun;9(2):103-8
pubmed: 20687393
Dtsch Med Wochenschr. 2013 Oct;138(42):2146-50
pubmed: 23873176
Neuropsychobiology. 1998 Nov;38(4):222-5
pubmed: 9813461
J Endocrinol Invest. 2012;35(6 Suppl):36-9
pubmed: 23014072
Am J Psychiatry. 1990 Jan;147(1):94-9
pubmed: 2293795
J Clin Psychiatry. 1987 Mar;48 Suppl:12-8
pubmed: 3029044
Endocr Rev. 2008 Feb;29(1):76-131
pubmed: 17991805
J Clin Psychiatry. 1993 Feb;54(2):47-54
pubmed: 8444820
Arch Med Res. 2002 Nov-Dec;33(6):552-6
pubmed: 12505101